Axsome Malta Ltd v. Aurobindo Pharma USA Inc

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Axsome Malta Ltd. (Malta) and Axsome Therapeutics, Inc. (Delaware)
  • Defendant: Aurobindo Pharma USA, Inc. (Delaware) and Aurobindo Pharma Limited (India)
  • Plaintiff’s Counsel: Saul Ewing LLP
• Case Identification: 2:26-cv-01580, D.N.J., 02/18/2026
• Venue Allegations: Plaintiff alleges venue is proper in the District of New Jersey because Defendant Aurobindo Pharma USA, Inc. maintains a regular and established place of business in the district, and the district will be a destination for the accused generic drug products. Venue over the foreign parent, Aurobindo Pharma Limited, is alleged based on its status as a foreign company.
• Core Dispute: Plaintiff alleges that Defendant’s submission of an Abbreviated New Drug Application (ANDA) to market a generic version of Plaintiff's Sunosi® (solriamfetol) oral tablets constitutes an act of infringement of a patent directed to a specific crystalline form of the active pharmaceutical ingredient.
• Technical Context: The dispute is in the field of pharmaceutical chemistry, specifically concerning polymorphs, which are different crystalline structures of the same chemical compound that can affect a drug's stability, solubility, and manufacturing.
• Key Procedural History: The litigation was triggered by Defendant Aurobindo's submission of ANDA No. 218725 and its associated Paragraph IV Certification, which asserts that U.S. Patent No. 12,384,743 is invalid and/or will not be infringed by its proposed generic product. The complaint also notes other pending litigation between the parties concerning different patents listed in the Orange Book for the same drug product.

Case Timeline

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 12,384,743 - Compositions comprising (R)-2-amino-3-phenylpropyl carbamate and uses thereof

The Invention Explained

• Problem Addressed: The patent addresses shortcomings in prior art methods for producing (R)-2-amino-3-phenylpropyl carbamate ("APC"), the active ingredient in Sunosi® (solriamfetol) (ʼ743 Patent, col. 1:44-47). Specifically, the patent identifies the need for a method of preparing APC that minimizes contamination with 2-chloropropane, described as a "potential genotoxic impurity" that could appear during crystallization ʼ743 Patent, col. 6:40-43
• The Patented Solution: The invention claims to identify and characterize specific crystalline forms (polymorphs) of APC hydrochloride ʼ743 Patent, abstract While the specification describes both an anhydrous "Form A" and a hemihydrate "Form B," the asserted independent claim is directed specifically to Form A ʼ743 Patent, col. 8:45-48 ʼ743 Patent, claim 1 By defining a specific, stable crystalline form, the invention provides a basis for creating a consistent and pure drug product. The patent also describes a method for producing APC with increased purity ʼ743 Patent, abstract
• Technical Importance: Controlling the polymorphic form of an active pharmaceutical ingredient is critical for ensuring product consistency, stability, and bioavailability, which are key considerations for both manufacturing and regulatory approval ʼ743 Patent, col. 8:40-44

Key Claims at a Glance

• The complaint asserts infringement of at least independent claim 1 Compl. ¶30
• The essential elements of Claim 1 are:
  • Crystalline (R)-2-amino-3-phenylpropyl carbamate hydrochloride
  • having an X-ray powder diffraction pattern as shown in FIG. 1 Form A
• The complaint alleges infringement of "one or more of the claims," which may suggest an intent to assert dependent claims later in the litigation Compl. ¶30

III. The Accused Instrumentality

Product Identification

The accused instrumentality is "Aurobindo's Proposed Product," a generic version of solriamfetol oral tablets for which Aurobindo submitted ANDA No. 218725 to the FDA for marketing approval Compl. ¶¶1, 15

Functionality and Market Context

• The complaint alleges that Aurobindo's Proposed Product is a generic version of Axsome’s Sunosi®, a dopamine and norepinephrine reuptake inhibitor indicated to improve wakefulness in adults with excessive daytime sleepiness Compl. ¶¶1-2, 9
• The filing of the ANDA itself is the statutory act of infringement under 35 U.S.C. § 271(e)(2)(A) Compl. ¶30 The complaint alleges that upon FDA approval, Aurobindo will manufacture, use, sell, and import its generic product in the United States Compl. ¶25
• No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

The complaint pleads infringement at a high level, as is common in Hatch-Waxman cases initiated by a Paragraph IV notice. It alleges that the act of submitting the ANDA constitutes infringement of at least claim 1, without providing a detailed element-by-element analysis or technical evidence Compl. ¶30

’743 Patent Infringement Allegations

Identified Points of Contention

• Factual Question: The central issue will be a factual one: does the solriamfetol hydrochloride in Aurobindo's Proposed Product, as formulated for its ANDA, actually exhibit the specific X-ray powder diffraction (XRPD) pattern of "Form A" as shown in Figure 1 of the patent? The litigation will likely focus on discovery related to Aurobindo's ANDA submission and expert analysis of its product samples.
• Scope Question: A potential dispute may arise over the scope of the phrase "as shown in FIG. 1 Form A." The analysis will question whether this language requires an exact match to the depicted XRPD pattern or if it can encompass patterns that are substantially similar, accounting for routine experimental variation.

V. Key Claim Terms for Construction

The complaint does not provide sufficient detail for a full analysis of claim construction disputes. However, based on the technology, the following term is central.

• The Term: "having an X-ray powder diffraction pattern as shown in FIG. 1 Form A"
• Context and Importance: This limitation defines the entire scope of the asserted claim. In pharmaceutical patent litigation involving polymorphs, the interpretation of such defining characteristics is paramount. The outcome of the infringement analysis will depend entirely on whether Aurobindo's product is found to meet this structural definition. Practitioners may focus on this term because any difference between the accused product's XRPD pattern and the one depicted in the patent's Figure 1 could be a basis for a non-infringement defense.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The patent does not appear to contain explicit language, such as "substantially as shown," that would support a broad reading of this limitation for Form A. A party arguing for a broader scope might rely on the general understanding in the art that XRPD patterns can have minor variations due to sample preparation or instrument settings.
  • Evidence for a Narrower Interpretation: The claim language "as shown in FIG. 1 Form A" is highly specific and points to a single figure without qualification ʼ743 Patent, claim 1 The specification distinguishes this "Form A" from another polymorph, "Form B," suggesting that the forms are meant to be viewed as distinct structures ʼ743 Patent, col. 8:45-48 ʼ743 Patent, col. 8:56-57 This specificity may support a narrow construction that requires a very close correlation to the depicted pattern.

VI. Other Allegations

• Indirect Infringement: The complaint includes forward-looking allegations of induced and contributory infringement that would occur upon FDA approval and commercial launch of Aurobindo's product Compl. ¶¶33-34 It alleges inducement based on knowledge of the patent and intentional encouragement of infringing acts Compl. ¶33 It alleges contributory infringement on the basis that the product is designed for an infringing use and lacks a substantial non-infringing use Compl. ¶34
• Willful Infringement: The complaint does not explicitly plead "willful infringement." However, it alleges that Aurobindo had knowledge of the ʼ743 Patent via its Paragraph IV certification Compl. ¶28, and it requests a finding that the case is "exceptional" and an award of attorneys' fees under 35 U.S.C. § 285 Compl. ¶37 Compl. Prayer for Relief (J)

VII. Analyst’s Conclusion: Key Questions for the Case

The resolution of this case will likely depend on the answers to two primary questions, one rooted in evidence and the other in claim interpretation.

• A core issue will be one of evidentiary proof: What does the scientific evidence, obtained through discovery and expert testing, reveal about the actual crystalline structure of the solriamfetol hydrochloride in Aurobindo's proposed generic product? Is it, in fact, the "Form A" polymorph claimed in the ʼ743 Patent?
• A key legal question will be one of definitional precision: How much deviation, if any, from the XRPD pattern depicted in the patent's "FIG. 1 Form A" is permissible before a product is considered non-infringing? The court's construction of this claim limitation will be critical to the case's outcome.